Alnylam Pharmaceuticals (NASDAQ:ALNY) Releases Earnings Results, Misses Expectations By $0.03 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY) released its earnings results on Thursday. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03), Zacks reports. Alnylam Pharmaceuticals updated its FY 2025 guidance to EPS.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY traded down $1.57 during trading on Thursday, hitting $264.40. 361,414 shares of the stock were exchanged, compared to its average volume of 665,671. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a market capitalization of $34.10 billion, a price-to-earnings ratio of -100.91 and a beta of 0.35. The company’s fifty day simple moving average is $253.77 and its 200-day simple moving average is $262.99. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75.

Analyst Ratings Changes

A number of research firms have recently weighed in on ALNY. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Piper Sandler reaffirmed an “overweight” rating and set a $296.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday. Finally, Wolfe Research lowered Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $298.61.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now owns 13,191 shares in the company, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Pushkal Garg sold 1,682 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $422,148.36. Following the transaction, the chief marketing officer now owns 17,457 shares of the company’s stock, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 73,964 shares of company stock valued at $20,622,925. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.